AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

HBM Healthcare Investments AG

Earnings Release Oct 3, 2022

893_rns_2022-10-03_65876867-fea5-473d-b271-a43c876925b3.html

Earnings Release

Open in Viewer

Opens in native device viewer

Ad hoc announcement pursuant to Art. 53 LR

HBM Healthcare Investments AG / Key word(s): Half Year Results

HBM Healthcare Investments publishes Net Asset Value per Share (NAV) of CHF 270.92 as at 30 September 2022

03-Oct-2022 / 17:47 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


The net asset value per share (NAV) as at 30 September 2022 amounts to CHF 270.92 and is thus 1.7 percent lower than at the beginning of the current financial year 2022/23. In comparison, the MSCI World Health Care Sector Index declined by 7.7 percent and the Nasdaq Biotechnology Index by 3.1 percent.

Based on the reported NAV, HBM Healthcare Investments expects a loss of CHF 34 million for the first half of the year. The result was significantly influenced by the listed investment in Cathay Biotech. The company's market capitalisation on the Shanghai Stock Exchange fell by slightly more than one fifth. Cathay Biotech, a leader in the growth market of synthetic biology, is debt-free, profitable and shows continuously increasing sales and profits. The remaining private and listed investments in the portfolio developed positively in value overall. This is also thanks to the four acquisitions of Sierra Oncology, Biohaven, Turning Point Therapeutics and most recently ChemoCentryx from the portfolio of listed companies. 

The figures presented here are the preliminary result based on the current status of the closing process. The definitive result will be published with the half-year report on 21 October 2022. 

Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at [email protected] .


End of Inside Information


Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: [email protected]
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 1455715
End of Announcement EQS News Service

1455715  03-Oct-2022 CET/CEST

Talk to a Data Expert

Have a question? We'll get back to you promptly.